Article

Adjuvant IL-2 offers survival benefit in metastatic RCC

Author(s):

Orlando, FL-In patients with metastatic renal cell carcinoma, adjuvant interleukin-2 (IL-2) after cytoreductive nephrectomy appears to offer a superior survival benefit over nephrectomy followed by interferon alpha-2b, according to a report presented here at the American Society of Clinical Oncology annual meeting.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

© 2025 MJH Life Sciences

All rights reserved.